Campbell Soup Co. (NYSE: CPB) said on Tuesday that it is launching a brand new, $100 million “It’s Amazing What Soup Can Do,” Ad campaign to help promote its soup brands, the company is hoping to turn the their soup business around.

Over the past year, sales of soup have decreased as steep competition increases from low costing meals such as frozen entrees and pizza. Last week Campbell’s said that sales of both ready-to-serve and condensed soups dropped 7 percent in the fourth quarter. Cutting costs helped net income increase 63 percent, while total sales were down 1 percent compared with the prior year quarter.

Campbell’s new ad campaign is called “It’s Amazing What Soup Can Do,” and includes TV commercials which will include  actor Tim Allen’s voice, along with print, radio and online ads. The company says that the campaign is “significantly” larger than any previous ad campaign. Ads started running last Sunday.

Shares dropped 48 cents to $35.73 during morning trading.

Emdeon Inc. (NYSE: EM) announced on Tuesday that they have agreed to buy to privately held Chamberlin Edmonds & Associates Inc. for $260 million in cash.

Chamberlin Edmonds helps hospitals to reduce uncompensated care and lower bad debt expenses. The company, who is based in Atlanta  works with uninsured patients to help them navigate Medicaid, Social Security, disability and charity care programs. Currently working with 200 acute care facilities through out 30 states.

George Lazenby, Emdeon’s CEO said in a statement .”The acquisition of Chamberlin Edmonds continues Emdeon’s strategic expansion into technology-enabled services that drive meaningful value for our customers and make healthcare more efficient,”

“As government programs continue to expand under healthcare reform, hospitals will need better tools to lower the rate of uncompensated care and increase cash flows. The combined company will be able to offer enhanced revenue cycle services designed to help providers navigate the complex systems related to government reimbursement.”

For the six-months  Chamberlin Edmonds’ revenue was approximately $46.3 million for the six months ending June 30. The acquisition is subject to regular closing conditions and both companies expect to close in the fourth quarter of 2010.

Emdeon shares dropped 17 cents to $10.34 during morning trading.

Oracle Corp. (Nasdaq: ORCL) announced late Monday evening that they have hired former Hewlett-Packard Co. (NYSE: HPQ)CEO Mark Hurd to be Co President of the company. The news comes a month after he resigned from HP following a sexual harassment investigation.

Oracle said in a statement on Monday, Mark Hurd will replace Charles Phillips, who has resigned the same day. Phillips was co-president alongside Safra Catz, who will remain in her position with the company.

The company added in the statement that Hurd will also serve as a member of the board of directors and will report to his close friend Larry Ellison.

CEO Larry Ellison had criticized HP’s decision to force Hurd to resign, calling the actions of HP’s board “cowardly”.

“Mark did a brilliant job at H.P., and I expect he’ll do even better at Oracle,” “There is no executive in the I.T. world with more relevant experience than Mark.” Oracle chief executive Ellison said in a statement on Monday.

In the statement Oracle co-presidents, Safra Catz, said about Hurd  “an outstanding executive and a proven winner…I look forward to working with him for years to come. As Oracle continues to grow we need people experienced in operating a $100 billion business.”

Oracle is the world’s third largest software maker, and currently is competing with HP as well as with IBM and SAP.

“I believe Oracle’s strategy of combining software with hardware will enable Oracle to beat IBM in both enterprise servers and storage,” Mark Hurd said in a statement on Monday.

Oracle Corp. shares jumped more than 7% to $24.67 on Tuesday morning.

The Food and Drug Administration said that it will allow ProAmatine, also known as midodrine a Shire PLC (Nasdaq: SHPGY) low blood-pressure treatment to be kept on the market. The news comes after warning in August that the drug has yet to be proven effective.

Sandy Walsh, Food and Drug Administration representative said in a statement that that the federal agency will continue to allow consumers to access to ProAmatine saying “while the necessary data is collected and the legal issues get sorted out.

The FDA had proposed a withdrawal from the market for the drug and awaited Shire to schedule a meeting with the administration. ProAmatine was approved in 1996 based on great early results in treating low blood pressure. A follow-up study to show long-term benefits of the drug was never done and is mandatory.

Last year, Approximately 100,000 U.S. patients were prescribed ProAmatine or generic versions, according to the FDA.

Shire had originally decided to remove the drug from the market on Sept. 30. But the company no longer intends to do so.

Copies of the letter from the FDA  were sent to five generic companies who make the drug also, including Mylan Inc. and Novartis AG unit Sandoz Inc. The generic versions could be subject to market withdrawal, unless the manufacturers complete the study required.